When they compared the records of patients prescribed GLP-1 agonists, they found significantly more cases of pancreatitis, gastroparesis and bowel obstruction than in people who used bupropion-naltrexone
FDA Disclaimer : These statements have not been evaluated by the Food and Drug Administration
In general, patients may qualify if they have a BMI of 30 or higher, or a BMI of 27 or higher with a related condition such as high blood pressure , high cholesterol, or type 2 diabetes
Persistent or severe gastrointestinal symptoms while on GLP-1 therapy, such as severe nausea, vomiting, diarrhea, or severe abdominal pain, should prompt immediate medical evaluation
Before committing to any program, the details matter
Many patients who could not access insurance coverage or afford out-of-pocket brand-name pricing turned to compounded alternatives offered through telehealth platforms at lower price points